StockData

Capricor Therapeutics vs ProQR Therapeutics

CAPR and PRQR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CAPR and PRQR compare

ProQR Therapeutics scores higher on the StockData Score (7 against 6 for Capricor Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCAPRPRQR
Size and price
Market cap$483M–
Share price$8.30$1.18
Change, 1 year43.8%−45.4%
Change, 5 years143%−83.6%
Beta (5Y)0.432.55
Employees23159
StockData Score
Total score67 (better)
Valuation score1 (better)0
Growth score02 (better)
Performance score02 (better)
Health score5 (better)3
Dividend score00
Valuation
P/B2.0×–
FCF yield−23.8%–
Growth
Revenue growth (TTM)–11.4%
Profitability
Operating margin–−233%
Net margin–−229%
FCF margin–−273%
Return on equity−73.7%−57.4% (better)
Financial health
Debt / equity0.000.06 (better)
Current ratio7.35 (better)3.49
Altman Z-score0.39–
Piotroski F-score3 (better)1
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions67.6%57.6%
Held by insiders1.6%37.8%
Insider net buying, 12 months−$8.4M$1.3M (better)
Short interest, % of float32.8%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.